All In Biotech

Free tool

FAERS Monitor: Xofluza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214410 or its brand name (Xofluza, Baloxavir Marboxil). Reports on generic versions are filed under their own applications.

Reports

2,319

Serious

1,231

53% of reports

Hospitalization

455

Death reported

136

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event547
  • off label use427
  • intentional product use issue283
  • diarrhoea136
  • vomiting132
  • pneumonia115
  • drug ineffective90
  • nausea75
  • rash70
  • hyperpyrexia68
  • headache64
  • influenza60
  • colitis ischaemic57
  • pyrexia55
  • cough45

Reports by year received

View as table
YearReports
20171
201824
2019814
2020652
202156
202284
2023161
2024123
2025250
2026154

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,840 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperpyrexiaSignal68148.0116.99,629
colitis ischaemicSignal5777.359.74,181
intentional product use issueSignal28329.426.37,740
no adverse eventSignal54727.525.514,000
influenzaSignal604.93.8182
off label useSignal4274.44.11,177
pneumoniaSignal1153.22.7177
vomitingSignal1322.52.2125
diarrhoea1361.91.660
rash701.51.210
cough451.51.16
pyrexia551.41.17
headache640.90.70
nausea750.90.72
drug ineffective900.60.522

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.